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Abstract: Crizotinib is an effective drug for patients with anaplastic lymphoma kinase (ALK)-positive
non-small-cell lung cancer (NSCLC), but upon treatment, the tumors inevitably become crizotinib
resistant in time. The resistance mechanisms are only partly understood. In this study, we aim to
identify gene mutations associated with resistance in ALKpositive advanced non-squamous NSCLC
treated with crizotinib. Four ALK positive patients with progressive disease following crizotinib
treatment were identified with paired pre- and post-crizotinib tumor tissue from our previously
published cohort. Somatic variants in these samples were detected by whole exome sequencing.
In one of the four patients, an ALK-resistance associated mutation was identified. In the other
three patients, no ALK-resistance associated mutations were present. In these patients we identified
89 relevant somatic mutations in 74 genes that were specific to the resistant tumors. These genes were
enriched in 15 pathways. Four pathways, were related to epithelial-mesenchymal transition (EMT):
proteoglycans in cancer, HIF-1 signaling, FoxO signaling pathway, and ECM-receptor interaction.
Analysis of other EMT-related pathways revealed three additional genes with mutations specific
to the crizotinib-resistant tumor samples. The enrichment of mutations in genes associated with
EMT-related pathways indicates that loss of epithelial differentiation may represent a relevant
resistance mechanism for crizotinib.
Keywords: whole exome sequencing; adenocarcinoma; ALK; crizotinib resistance
1. Introduction
Lung cancer is the leading cause of cancer-related deaths worldwide [1]. In the traditional clinical
classification, there are two major types of lung cancer, small cell lung cancer, and non-small-cell lung
carcinoma (NSCLC) [2]. NSCLC is further subdivided into the major categories of squamous cell
carcinoma, adenocarcinoma, and large cell carcinoma, with adenocarcinoma being the most common
subtype [2]. Over the last decade, clinical management and treatment of lung cancer patients has
become more dependent on molecular classification using “driver” mutations that occur in genes,
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such as anaplastic lymphoma kinase (ALK), epidermal growth factor receptor (EGFR), and c-Ros
oncogene 1 (ROS1) [3–5]. Around 5% of all adenocarcinomas have a chromosomal inversion or
translocation that produces a fusion product consisting of the kinase domain of ALK combined with
EML4 or another fusion partner [5,6]. Tumor cells with an ALK fusion are highly sensitive to tyrosine
kinase inhibitors (TKIs) that target ALK, which include crizotinib and the second-generation ALK
inhibitors, ceritinib, brigatinib, and alectinib [7–10]. However, most patients will inevitably acquire
resistance to ALK-TKI treatment, usually within one year [11,12].
The mechanisms of resistance can be ALK-dependent or ALK-independent [13]. Secondary
ALK mutations are observed in 25–33% of patients progressing to crizotinib treatment, and the
number of mutations increases to approximately 50% after using a second-generation TKI [14]. Several
ALK-independent resistance mechanisms have been proposed based on studies in post-crizotinib
tumor samples and cell line models [15–20]. These mechanisms include alterations of EGFR,
proto-oncogene receptor tyrosine kinase (KIT), and Insulin like growth factor 1 receptor (IGF1R),
as well as activation of the MAP kinase, PI3K/AKT, RAS/MAPK, and JAK/STAT pathways. Studies
based on resistant and sensitive cell lines and those based solely on post-resistant tumor tissues have
suggested that the epithelial-mesenchymal transition (EMT) potentially mediates resistance against
ALK inhibitors [21–23]. However, the level of evidence is variable and our understanding of the
mechanisms that are involved in crizotinib-resistance remains incomplete.
In this study, we aimed to identify somatic mutations related to crizotinib resistance using whole
exome sequencing (WES) of paired tumor biopsies from advanced adenocarcinoma patients, taken both
before crizotinib treatment and upon disease progression to crizotinib.
2. Results
2.1. Patients
Four patients (ALK4, ALK6, ALK14, and ALK16) developed crizotinib resistance after initially
responding to treatment for approximately one year (Table 1 and Figure 1). One patient, ALK8, did not
respond to crizotinib treatment at all and died 2.5 months after initiating crizotinib. ALK6 and ALK16
died 15 months and 10 months, respectively, after crizotinib treatment. At the time of this study,
ALK4 and ALK14 were still alive 3.8 and 3 years, respectively, after developing crizotinib resistance.
Upon developing resistance, ALK4 was treated with ceritinib and ALK14 with alectinib. Patients ALK6
and ALK16 had not been treated with 2nd or 3rd generation ALK inhibitors, because those drugs were
not available at that time.
Table 1. Characteristics of the five anaplastic lymphoma kinase (ALK) positive advanced non-small-cell








Primary 4 Resistant 5
ALK4 female 34 15.9 non-smoker ovary liver
ALK6 male 55 9.5 past-smoker (15) cervical lymph node glenoid
ALK8 male 76 1.6 past-smoker (NA 3)
lymph node
mediastinal 4 right not done
ALK14 female 62 8.4 current smoker (20) brain occipitalmetastasis
mediastinal
lymph node 7
ALK16 female 48 5.1 past-smoker (18) lung lung
1 PFS: progression-free survival (time from start of treatment to disease progression estimated by CT); 2 py: pack years;
3 NA: not available; 4 Primary: primary tumor biopsy; 5 Resistant: resistant tumor biopsy.
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Figure 1. Schematic representation of the total period of treatment and follow-up per patient, 
indicated by a horizontal black line. ALK4 and ALK14 were alive at the end of study; ALK6, ALK8 
and ALK16 died before the end of study). Blocks indicate the duration of crizotinib treatment. 
Arrows indicate when pre- and post-crizotinib tissue samples were collected. Notes: ALK4 was 
treated with several lines of chemotherapy and radiotherapy. ALK4’s second biopsy was taken from 
a local relapse, and crizotinib was continued. Ceritinib was started at further disease progression. 
Patient ALK6, ALK14, ALK16 received first-line chemo (radio) therapy before the first biopsy. For 
patient ALK8, crizotinib treatment was stopped after 1.6 months upon disease progression. ALK14 
had ongoing response to alectinib subsequent to the crizotinib treatment. ALK16 was treated with 
ceritinib for eight months following crizotinib treatment. 
2.2. Whole Exome Sequencing 
WES generated an average of 60 × 106 unique reads per sample that passed the Illumina quality 
filtering steps (Supplementary Table S1). On average, 98% of the unique reads could be aligned to 
the human reference genome. The mean coverage per sample was 66× with 86% of the target region 
being covered at least 20×. We identified 582 variants in 519 genes across the four patients who had 
developed resistance. Of these variants, 20% (116 single-nucleotide variants (SNVs) in 143 genes) 
had Combined Annotation Dependent Depletion (CADD) scores ≥ 20, 45% (265 SNVs in 253 genes) 
had CADD scores between 10 and 20, and 26% (151 SNVs in 101 genes) had CADD scores < 10. For 
9% of the variants (50 variants in 47 genes), no CADD score was available. Most of the variants 
without CADD scores (n = 46) were small insertions or deletions (INDELs), of which 25 were out of 
frame INDELs and should be considered as being deleterious.  
We analyzed the validity of the WES data using two independent approaches. First, we 
reanalyzed RNA-seq data from our published study that included the crizotinib-resistant tumor 
samples of ALK4 and ALK6 patients [24]. A ≥ 10× coverage at the variant position was observed for 
95 out of the 169 WES variants in ALK4 and 34 of the 61 WES variants in ALK6. Ninety out of the 95 
variants (95%) in ALK4 and 29 of the 34 variants (85%) in ALK6 were consistent with those that 
were identified in the WES data, indicating that the majority of the mutant alleles were also 
expressed in these tumor samples. Our second validation approach was based on an independent 
WES analysis. After filtering for ≥10× coverage at the variant position, we could evaluate 67 variants 
in ALK4 and 42 variants in ALK6. We confirmed 61 variants (91%) in ALK4 and 40 variants (95%) 
in ALK6. When combining both strategies, we independently validated 114 of 123 (93%) variants in 
ALK4 and 45 of 48 (94%) variants in ALK6. 
2.3. Variants Related to Crizotinib Treatment 
When comparing the primary tumors with the resistant tumors for the four patients with 
paired samples revealed 175 putatively “treatment-related” variants in 156 genes, of which 136 
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e analyzed the validity of the WES data using two independent approaches. First, we reanalyzed
RNA-seq ata from our published study that include the crizotinib-resistant tumor samples of ALK4
and ALK6 patients [24]. A ≥ 10× coverage at the variant position was observed for 95 out of the
169 WES variants in ALK4 and 34 of the 61 WES variants in ALK6. Ninety out of the 95 variants (95%)
in ALK4 and 29 of the 34 variants (85%) in ALK6 were consistent with those that were identified in
the WES data, indicating that the majority of the mutant alleles were also expressed in these tumor
samples. Our second validation approach was based on an independent WES analysis. After filtering
for ≥10× coverage at the variant position, we could evaluate 67 variants in ALK4 and 42 variants in
ALK6. We confirmed 61 variants (91%) in ALK4 and 40 variants (95 ) in L 6. When combining both
strategies, we independently validated 114 of 123 (93%) variants in ALK4 and 45 of 48 (94%) variants
in ALK6.
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2.3. Variants Related to Crizotinib Treatment
When comparing the primary tumors with the resistant tumors for the four patients with paired samples
revealed 175 putatively “treatment-related” variants in 156 genes, of which 136 variants (in 129 genes) were
only found in the resistant tumor (Figure 2) (Supplementary Table S2). CADD scores > 20, indicative of
deleterious variants, were observed for 16% of these variants (21 SNVs in 15 genes), whereas 43% (75 SNVs
in 71 genes) had CADD scores between 10 and 20, 30% (53 SNVs in 49 genes) had CADD scores < 10,
and 11% (19 INDELs in 19 genes) had no CADD scores (Supplementary Table S2). Fifteen INDELs caused
a frameshift, and can thus be considered deleterious. The distribution of the variants over the different
CADD score groups was similar to the distribution observed for all the somatic variants.
Cancers 2018, 10, 10 4 of 12 
 
variants (in 129 genes) were only found in the resistant tumor (Figure 2) (Supplementary Table S2). 
CADD scores > 20, indicative of deleterious variants, were observed for 16% of these variants (21 
SNVs in 15 genes), hereas 43% (75 SNVs in 71 genes) had CADD scores bet een 10 and 20, 30% 
(53 SNVs in 49 genes) had CADD scores < 10, and 11% (19 INDELs in 19 genes) had no CADD 
scores (Supplementary Table S2). Fifteen INDELs caused a frameshift, and can thus be considered 
deleterious. The distribution of the variants over the different CADD score groups was similar to 






























































86 33 43 14 
ALK4 ALK6 ALK14 ALK16 
 
Figure 2. Comparison of mutant read frequencies (MRF) in primary tumor samples (x-axis) and 
resistant tumor samples (y-axis) from four patients. Each dot represents a single variant. Variants 
shown in the dashed trapezium have a MRF ≥ 0.20 in resistant samples and at least a two times 
higher MRF in the treatment-related sample as compared to the primary sample. The total number 
of “treatment-related” variants in each patient is indicated in the trapezium. In total, 176 variants 
were identified in 156 genes. 
To focus on ALK-independent resistance mechanisms, we excluded genes that were mutated in 
ALK4 because the resistant tumor carried a known ALK-resistance-associated mutation (ALK 
G1269A) that explained the crizotinib resistance. The three remaining paired pre- and post-
treatment tumors had a total of 90 putatively “treatment-related” variants in 74 genes. Each gene 
was mutated in only one of the three patients. The 74 genes were involved in 105 pathways. A 
significant enrichment was observed for 15 pathways in Partek Genomics Suite 6.6 (Supplementary 
Table S3). Four of these pathways, harboring nine treatment-related mutated genes, were linked to 
a common biological theme: EMT. These EMT pathways were proteoglycans in cancer, HIF-1 
signaling, FoxO signaling, and ECM-receptor interaction (Table 2). Using the Database for 
Annotation, Visualization and Integrated Discovery (DAVID) pathway analysis tool, we confirmed 
significant enrichment of proteoglycans in cancer and the HIF-1 signaling pathways, and found 
borderline significance for the FoxO signaling pathway. Using the Gene Network analysis tool, we 
found a borderline significant enrichment for the ECM-receptor interaction pathway but also that 
the other three pathways were not present in Gene Network. Analysis of the other EMT-related 
pathways in Partek [23] revealed three additional genes with treatment-related mutations (Table 2). 
In total we found 12 genes uniquely mutated in the resistant tumors that are linked to 13 EMT-
related pathways. Variants of six of these genes (ARNT, CTNNA3, PTPN11, MLTK, SMAD4, and 
VEGFA) had CADD scores higher than 20. Another two genes, LAMA2 and MLTK, had out-of-
frame INDELs, which should be damaging.  
Figure 2. Comparison of mutant read frequencies (MRF) in primary tumor samples (x-axis) and
resistant tumor samples (y-axis) from four patients. Each dot represents a single variant. Variants
shown in the dashed trapezium have a MRF ≥ 0.20 in resistant samples and at least a two times
higher MRF in the treatment-related sample as compared to the primary sample. The total number of
“treatment-related” variants in each patient is indicated in the trapezium. In total, 176 variants were
identified in 156 genes.
To focus on ALK-independent resistance mechanisms, we excluded genes that were mutated in
ALK4 because the resistant tumor carried a known ALK-resistance-associated mutation (ALK G1269A)
that explained the crizotinib resistance. The three remaining paired pre- and post-treatment tumors had
a total of 90 putatively “treatment-related” variants in 74 genes. Each gene was mutated in only one of
the three patients. The 74 genes were involved in 105 pathways. A significant enrichment was observed
for 15 pathways in Partek Genomics Suite 6.6 (Supplementary Table S3). Four of these pathways,
harboring nine treatment-related mutated genes, were linked to a common biological theme: EMT.
These EMT pathways were proteoglycans in cancer, HIF-1 signaling, FoxO signaling, and ECM-receptor
interaction (Table 2). Using the Database for Annotation, Visualization and Integrated Discovery
(DAVID) pathway analysis tool, we confirmed significant enrichment of proteoglycans in cancer and
the HIF-1 signaling pathways, and found borderline significance for the FoxO signaling pathway. Using
the Gene Network analysis tool, we found a borderline significant enrichment for the ECM-receptor
interaction pathway but also that the other three pathways were not present in Gene Network. Analysis
of the other EMT-related pathways in Partek [23] revealed three additional genes with treatment-related
mutations (Table 2). In total we found 12 genes uniquely mutated in the resistant tumors that are
linked to 13 EMT-related pathways. Variants of six of these genes (ARNT, CTNNA3, PTPN11, MLTK,
SMAD4, and VEGFA) had CADD scores higher than 20. Another two genes, LAMA2 and MLTK,
had out-of-frame INDELs, which should be damaging.
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Table 2. Overview of all epithelial-mesenchymal transition (EMT)-related pathways that include genes
with resistance-related mutated in patients ALK6, ALK14, and ALK16.
Pathway Name Patient(s) Genes Mutated EnrichmentScore
Enrichment
p-Value 1
Proteoglycans in cancer 2 ALK6 ALK14
ANK2, FASLG, HSPG2,
PTPN11, STAT3, VEGFA 8.0 0.00
HIF-1 signaling pathway 2 ALK6 ALK14 ARNT, STAT3, VEGFA 4.3 0.01
FoxO signaling pathway 2 ALK6 ALK14 FASLG, SMAD4, STAT3 3.7 0.03
ECM-receptor interaction 3 ALK6 ALK14 HSPG2, LAMA2 3.3 0.04
Adherens junction 3 ALK6 ALK14 CTNNA3, SMAD4 3.0 0.05
Ras signaling pathway ALK14 FASLG, PTPN11, VEGFA 2.7 0.07
Jak-STAT signaling pathway ALK6 ALK14 PTPN11, STAT3 1.9 ns
PI3K-AKT signaling pathway ALK14 FASLG, LAMA2, VEGFA 1.8 ns
Focal adhesion 3 ALK14 LAMA2, VEGFA 1.6 ns
VEGF signaling pathway 3 ALK14 VEGFA 1.3 ns
TGF-beta signaling pathway ALK6 SMAD4 1.2 ns
MAPK signaling pathway ALK14 FASLG, MAP3K20 1.1 ns
Wnt signaling pathway 3 ALK6 SMAD4 1.0 ns
Regulation of actin cytoskeleton ALK6 SCIN 0.5 ns
1 p-value based on analysis with Partek; ns, not significant; 2 Borderline or significant in DAVID; 3 Borderline or
significant in Gene Network; Bold type indicates additional genes not included in the four pathways significantly
enriched in Partek.
In the one non-responding patient, ALK8, we observed somatic variants in three additional
EMT-related genes (ITGAM, CACNA1E, and RUVBL1). These three genes are involved in cell adhesion
molecules, MAPK signaling, Wnt signaling, and regulation of the actin cytoskeleton.
Immunohistochemistry (IHC) revealed changes in the E-cadherin and/or Vimentin staining
intensity compatible with EMT for only three out of 11 cases (patients ALK20, ALK25, and ALK26).
IHC was inconclusive for ALK14 and ALK16. This indicates that other resistant pathways may be
operational, although technical issues, such as scarcity of tumor tissue and differences in tissue origin,
hampered the reliability of our scoring.
Using a different analysis strategy, performing separate pathway analysis for genes mutated in
each individual patient we identified the metabolism pathway as the only pathway that was shared
by all five patients for whom we had paired primary and resistant tumor samples. In total, we found
15 variants in 13 genes from this pathway, of which four had CADD scores > 20 and one frameshift
insertion. The genes are indicated in Supplementary Table S2. One gene, CYP11B1, was also mutated
in the non-responding patient ALK8.
2.4. Treatment-Related Copy Number Alterations
We compared WES-based copy number alteration (CNA) plots of the primary tumors to those of
their paired resistant samples. Although we did identify several differences in CNAs between primary
and resistant samples (Supplementary Figure S1), we did not see a copy number gain in any of the
patients for the ALK, MET, or KIT loci known to be associated with resistance. Nor did we observe
recurrent CNAs in other parts of the genome shared between these patients.
3. Discussion
In this study, we identified 175 variants in 156 genes that are enriched in crizotinib-resistant
tumor samples as compared to matched pre-crizotinib samples. In the three patients without
ALK-resistance-associated mutations, pathway analysis revealed a significant enrichment of nine
genes in four EMT pathways. These four pathways were proteoglycans in cancer (ANK2, FASLG,
HSPG2, PTPN11, STAT3, and VEGFA), HIF-1 signaling (ARNT, STAT3, and VEGFA), FoxO signaling
(FASLG, SMAD4, and STAT3), and ECM-receptor interaction (HSPG2 and LAMA2). No convincing
differences in CNAs were observed between the primary and resistant tumor samples, making it
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unlikely that gene copy number gains were associated with the resistance that was observed in the
patients included in this study.
In our study, we have explored ALK-independent mechanisms of crizotinib resistance in advanced
NSCLC patients by comparing variants observed in the crizotinib-resistant tumor to the variants
present in the tumor before crizotinib treatment. Many mechanisms for crizotinib resistance have been
proposed based on cell line studies and studies using resistant samples without comparison to the
pre-treatment samples [25–27]. These studies revealed activation of several ALK-independent bypass
mechanisms, including activation of EGFR, KRAS, SRC, and ERBB and MAPK signaling [25–27].
Although these studies generated valuable data, a direct comparison between pre- and post-crizotinib
treatment samples is required to truly pinpoint the causal resistance-associated alterations.
Despite the relatively large number of patients in our previous paper, the total number of
patients with matched samples eligible for this study was limited. A general problem in the clinic
is the lack of re-biopsies from the growing tumor upon development of resistance. In patients with
re-biopsies, the tumor cell percentages are usually low and the biopsy is often fully consumed by the
routine diagnostic molecular tests needed to guide further treatment. The limited DNA quality of
formalin-fixed paraffin-embedded (FFPE) tumor samples resulted in a suboptimal coverage for part of
the exons, which may have prevented the detection of mutations that are present in small subclones
of the tumor. However, this should not have affected the identification of treatment-related driver
mutations, because they should be present in the majority of the tumor cells in the resistant samples.
With regard to ALK-dependent mechanisms, we observed an ALK G1269A mutation in the
resistant tumor of patient ALK4. This mutation was not detected in the primary tumor, as consistent
with our previous study using RNAseq on the resistant tumor and ddPCR to analyze the primary
tumor sample [14]. This ALK gatekeeper mutation has been reported previously in several other
studies as a resistance mechanism to crizotinib treatment in ALK-positive NSCLC patients [21,28,29].
For the remaining three patients, no ALK gatekeeper mutations were found, indicating the
activation of ALK-independent bypass mechanisms. Here, we focused on treatment-related variants
specific for, or with increased mutant read frequencies (MRFs) in, post-treatment samples. In addition
to crizotinib treatment, there are several other factors that may have contributed to what we define as
treatment-related variants. These factors include treatment history, time interval between biopsies,
and differences in anatomic location of the biopsies. Indeed, in patient ALK16, whose biopsies are
taken from the same anatomic location, the number of putative treatment-related variants is low.
However, development of crizotinib resistance is the common factor in these patients, and thus we can
assume that at least a subset of the mutations is directly related to crizotinib resistance. Since there was
no commonly mutated gene in these three patients, ALK-independent mechanisms appear to be more
diverse, a finding that is consistent with the broad variations in resistance mechanisms proposed in the
literature [15,28]. To find a possible common mode of action, we performed pathway analysis on the
treatment-related resistance genes in these three patients. Four of the significantly enriched pathways
were EMT related. Our subsequent analysis of additional EMT-related pathways revealed a total of
12 mutated genes in two of the three patients with ALK-independent resistance mechanisms. Several
studies have indicated EMT as a mediator of resistance against ALK inhibitors [21–23]. Silencing of
Vimentin restored the responsiveness of a crizotinib-resistant cell line to ALK inhibitors [22], whereas
in another cell line, the responsiveness to NMS could not be restored [23]. Nevertheless, both of
the studies support a role of EMT in crizotinib resistance. Five out of eleven ALK-positive NSCLC
patients treated with the second-generation ALK inhibitor ceritinib showed EMT involvement based
on immunostaining for E-cadherin and Vimentin [21]. In our study, seven out of the 12 mutated
genes involved in EMT had variants that may potentially impact the protein, based on either a
CADD score >20 or the presence of out-of-frame INDELs.
Among the seven mutated genes with high CADD scores, SMAD4 is known to be a crucial
regulator of the TGF-beta signaling pathway, which is one of the most important mechanisms leading
to EMT [24]. The SMAD4 W323* mutation observed in ALK6 is in the same functional MH2-domain
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as the commonly observed R361H and R361C hotspot mutations. This supports a potential causal role
for the SMAD4 W323* mutation. PTPN11 positively regulates TGF1-induced EMT in lung cancer [30],
and the PTPN11 E76K mutation that is detected in ALK14 was proven to be an activating mutation
in lung cancer cells [31]. Overexpression of VEGFA in breast cell lines induced SNAIL protein levels,
which further reduced E-cadherin expression levels [32]. This suggests that if the VEGFA G328R
observed in ALK14 is indeed an activating mutation, it may induce loss of E-cadherin. The relevance
of the other four genes with high CADD score mutations (ARNT F446L, CTNNA3 E690K, and MLTK
F157L) or a deleterious out-of-frame deletion (LAMA2 P596Sfs*13) remains unclear.
Immunostaining for EMT-related protein expression was inconclusive in the subset of available
paired pre- and post-treatment samples. This was due to difficulties in scoring caused by differences in
tissue origin and scarcity of tumor cells. Moreover, the four EMT-related pathways that are discussed
above are also involved in various other biological processes, and these processes might also be
related to resistance independent of their association with EMT. Additional cases need to be studied
to fully explore the resistance mechanisms that are related to crizotinib resistance. Thus, our data
cannot exclude that additional pathways may be involved in the resistance. The metabolism pathway
may be a good candidate: it is the only pathway implicated in all five patients and dysregulation
of the metabolism pathway has been linked to drug resistance in various types of cancer [33,34].
PDE4D (Ser14Phefs*11), which was mutated in ALK16, was shown to impair cAMP generation
through cAMP hydrolysis in lung cancer cell lines. Inhibitors of PDE4 decrease cell proliferation and
angiogenesis [35]. Thus, inhibition of the metabolism pathway may provide additional mechanisms
for overcoming crizotinib resistance.
When crizotinib resistance occurs, second-generation ALK inhibitors (ceritinib, alectinib,
brigatinib), and, only subsequently, later-generation inhibitors (lorlatinib) are advised as next treatment
options, even when the ALK-gatekeeper mutation status is unknown [36]. A more optimal approach
would be to determine the presence of ALK-gatekeeper mutations in progressing tumors in order
to justify the choice of the next ALK inhibitor. It is unclear whether tumors that are driven by
ALK-independent resistance mechanisms also show tumor response to these drugs. In our study,
one of the three patients with an ALK-independent resistance mechanism had a good response to
alectinib, suggesting that this drug, in addition to being ALK-specific, may target ALK-independent
resistance mechanisms [37,38].
4. Materials and Methods
4.1. Patient Inclusion
In a previous study we described 29 ALK-positive non-squamous NSCLC patients who were
treated with crizotinib [12]. Their ALK status was assessed by immunohistochemistry. Patients involved
in our earlier study gave informed consent for the use of their biopsies for further analysis. For four of
these 29 patients, we had sufficient FFPE or frozen pre- and post-treatment tumor material to carry
out WES. The four patients are designated ALK4, ALK6, ALK14, and ALK16 in concordance with our
previous study [12]. In addition to these samples, we also had FFPE tumor material from one patient,
ALK8, who had no response to crizotinib. We had previously found an ALK G1269A gatekeeper
mutation in ALK4 by RNA-sequencing of the resistant tumor sample of this patient [14]. For each
patient, white blood cells were isolated from peripheral venous blood using standard protocols.
Tumor samples from patient ALK14 before crizotinib treatment and from patients ALK4 and ALK6
upon developing resistance to crizotinib treatment were fresh frozen. All the other tumor specimens
were FFPE. Macrodissection was applied to the tumor samples to achieve tumor cell content greater
than 60%. Patients provided informed consent for procurement of extra tumor tissue and analysis of
tissue specimen and was approved by the Medical Ethical Committee.
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4.2. DNA Isolation
DNA was isolated from blood and frozen samples using a standard salt-chloroform DNA isolation
protocol. For FFPE samples, DNA was isolated using the ReliaPrep™ FFPE gDNA Miniprep System
kit (Promega, Madison, WI, USA) following the manufacturer’s protocol. DNA concentrations were
measured by NanoDrop (Thermo Fisher Scientific Inc., Waltham, MA, USA), and DNA quality was
evaluated on a 1% agarose gel.
4.3. Whole Exome Sequencing
WES was carried out on 0.6–2 µg genomic DNA of normal and tumor-derived DNA samples
(BGI Tech Solutions Co. Ltd., Hong Kong, China). Target enrichment was done using the Agilent
SureSelect All Exon V5 kit (Agilent technologies, Santa Clara, CA, USA). Paired-end sequencing with a
read length of 2 × 90 nt was performed on Illumina HiSeq2000.
As a part of the validation procedure, we performed WES a second time on the crizotinib-resistant
samples from patients ALK4 and ALK6, following our previously published protocol and data analysis
pipeline [14]. RNA-sequencing data from ALK4 and ALK6 resistant samples were re-analyzed to
confirm the presence of mutations [14].
4.4. Immunohistochemistry
Eleven paired formalin-fixed tissue samples from our previous study (ALK1, ALK4, ALK5,
ALK6, ALK14, ALK16, ALK17, ALK20, ALK22, ALK25, and ALK26) were used for IHC staining of
two EMT biomarkers: E-cadherin (using mouse monoclonal E-cadherin 1:100, clone 36/E-cadherin;
BD Biosciences, Breda, The Netherlands) and Vimentin (using mouse monoclonal Vimentin 1:100,
clone sc-6260; Santa Cruz Biotechnology; Bioconnect, Huissen, The Netherlands).
4.5. Data Analysis
Raw reads were processed using our in-house pipeline, as described previously (24). In brief,
our variant calling pipeline is based on the Genome Analysis Toolkit (GATK) workflow and uses
Molgenis Compute as workflow management software [39]. Read alignment was done using
Burrows-Wheeler Aligner and GATK, using the human genome reference build GRCh37 with decoys
from the GATK bundle [39,40]. Picard Tools was used for format conversion and marking duplicates.
HaplotypeCaller was used for integrated calling of the variants for all of the samples from the same
patient/cohort. Variants were annotated using SnpEff/SnpSift with the Ensembl release 75 gene
annotations and the dbNSFP2.7 database [41]. GATK was used to identify variants. Variants were
annotated with dbsnp 138, Cosmic v72, 1000 genomes phase 3 and the ExAC 0.3 databases [42–44].
The data were filtered for quality metrics similarly to GATK recommendations using custom filters
for population frequency and variant effect. Based on the presence of variants in the normal sample,
germline variants were excluded from further analysis. Additionally variants were excluded if present
in 100 genomes phase 3 with a minor allele frequency > 0.02.
CADD scores were used to predict pathogenicity of the identified variants. Variants with
a CADD score ≥ 20 are defined as deleterious, those between 10 and 20 possibly deleterious, and those
<10 non-deleterious [45].
To identify somatic mutations we first excluded variants for which the total number of reads in
the normal sample was < 10. Next, we excluded all of the variants for which one or more mutant
reads were present in the normal sample. We then excluded variants with total reads < 10 in either the
primary or the resistant samples. The remaining variants, with two or more mutant reads in either the
pre-treatment tumor or post-treatment tumor samples, were considered somatic. Variants detected in
the resistant samples with MRFs ≥ 0.20, and for which the MRF is at least twice the MRF in the paired
primary sample, are indicated as “treatment-related” variants.
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Pathways overrepresented in the set of genes mutated specifically in the crizotinib-resistance
tumor samples were identified with the Partek Genomics Suite 6.6 software package (Partek Inc.,
St. Louis, MO, USA). In addition, we used Gene Network [46] and DAVID v6.8 [47] to validate our
findings by Partek.
4.6. WES-Based Analysis of CNAs
Pseudo probe data were generated with SAMtools VarScan2 and DNAcopy [48–50]. Briefly,
when frozen tumor tissue was used for the isolation of high quality DNA samples, pseudo-probe-derived
GC-normalized log2 copy number ratios were generated for each sample using the corresponding normal
sample. For FFPE tumor samples, we used WES data of a merged pool of normal FFPE samples as the
reference. All of the alignments with a mapping quality > 40, in combination with a minimal segment size
of 2 kb and a maximal segment size of 5 kb, with a mean base-wise coverage of at least 1×, were used to
calculate the ratios. DNA copy number variant calls were compared between the resistant and the primary
tumor sample based on assigned ploidity and by visual inspection of the copy number changes.
5. Conclusions
In conclusion, we have identified mutations in genes involved in EMT-related and metabolism
pathways in crizotinib-resistant tumors without ALK-gatekeeper mutations. From a clinical perspective,
the mutational status of patients may provide therapeutic guidance for clinical management of their
NSCLC by targeting loss of epithelial differentiation and/or metabolism pathways.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/10/1/10/s1.
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